Free Trial
NASDAQ:CELU

Celularity Q2 2025 Earnings Results & Report

Celularity logo
$0.61 -0.02 (-2.71%)
As of 02:50 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Celularity reported Q2 2025 earnings on August 29, 2025. The company reported EPS of -$1.02, while revenue was $5.74 million.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
After Market Closes
Conference Call
9:30 AM ET

Celularity EPS Results

Actual EPS
-$1.02
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 6 quarters

Celularity Revenue Results

Actual Revenue
$5.74 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Celularity Q2 2025 Earnings FAQ

Celularity (NASDAQ:CELU) reported earnings of -$1.02 per share for Q2 2025. The report was announced on Friday, August 29, 2025.

Celularity reported revenue of $5.74 million for Q2 2025.

Celularity Earnings Headlines

My $247 scanner for $7
Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment that covers a full year, with no subscription and no re-bills. Every night after the close, the scanner screens nearly a thousand of America's biggest stocks. It returns a short list of qualifying setups with the exact buy price next to each one. There's nothing to install. If you decide it's not for you, you get the $7 back and keep the scanner for the year.tc pixel
See More Celularity Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Celularity? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Celularity and other key companies, straight to your email.

About Celularity

Celularity (NASDAQ:CELU) is a biotechnology company that develops cell therapies and other products derived from the human placenta. Its platform uses cells collected after childbirth, which the company processes for potential use in regenerative medicine and treatment of disease.

The company’s research includes placental-derived natural killer cells and other cell types being developed for potential applications in cancer and other conditions. Its pipeline has included candidates such as CYNK-001, an investigational natural killer cell therapy.

Founded in 2016, Celularity is headquartered in Florham Park, New Jersey. Its work focuses on developing and manufacturing placenta-derived products for clinical and commercial use.

View Celularity Profile